Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 21

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 21
---
2 protein, respectively,
and resulted in decreased TCPP uptake in a variety of cancer cells, with a larger decrease observed when CD320 was knocked down. We subsequently
discovered that the simultaneous knockdown of these two cell-surface receptors, CD320 and LRP2, was deadly to cancer cells or inhibited
their growth significantly but left normal cells virtually unharmed.

We
designed siRNAs to effectively eliminate CD320 and LRP2 protein production to study their role in TCPP uptake into the cell. With these
CD320 and LRP2 siRNAs, we achieved a reduction of CD320 and LRP2 protein levels of up to 90%. Simultaneous siRNA knock-down of CD320
and LRP2 in normal cells, including skin fibroblasts and breast epithelial cells, did not affect cell growth. However, knock-down of
CD320 and LRP2 in cancer cell lines derived from diverse tissues (lung, breast, prostate, brain, and skin cancers) inhibited cell growth
or killed the cells, in some cases up to 80%. Interestingly, in some cell lines, when either CD320 or LRP2 were silenced individually,
a concurrent increase in protein expression of the other receptor was observed, suggesting that CD320 and LRP2 compensate for each other’s
function; hence, silencing both receptors is required for optimal cell killing.

 14 

Corporate
Information

We
were incorporated in the State of Delaware on March 26, 2014. Our principal executive office is located at 3300 Nacogdoches, Suite 216,
San Antonio, Texas 78217, and our telephone number at that address is (210) 698-5334. Our website address is https://www.bioaffinitytech.com/.
Information contained on or that can be accessed through our website is not incorporated by reference into this Annual Report. Investors
should not consider any such information to be part of this Annual Report.

Intellectual
Property Portfolio

We
strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent
protection intended to cover our commercialized diagnostic test, pipeline product candidates and their use, as well as other inventions
that are important to our business. In addition to patent protection, we also protect valuable company assets with copyright, trademark,
trade secret, and know-how through confidentiality agreements, invention assignment agreements, and a trade secret program to protect
aspects of our business